Novo Nordisk, Sanofi and MSD dominate the global diabetes drug market

Source: Xinkangjie diabetes medicine company on June 29, 2015 has caught up with a good opportunity According to a new report released by global data, the top ten global diabetes drug companies achieved sales revenue of US $62 billion in 2014, up 5.1% year on year Novo Nordisk, Sanofi and MSD are leading the pack with strong earnings from diabetes medicine products as these companies win in this rapidly growing global market Novo Nordisk successfully won the top ten positions of global data in global diabetes medicine sales revenue, relying on the sales revenue of US $11.3 billion of diabetes medicine in 2014 Novo Nordisk relies on its powerful GLP-1 products, liraglutide, Victoza and insulin detemir to boost its sales In addition, Novo Nordisk strives to maintain its dominant position through the following new products in the field of diabetes treatment drugs The new basic insulin, insulin deglucec and tresiba, has been listed in Europe In addition, ryzodeg, a combination of insulin degludec and tresiba and novorog, was approved for marketing in Mexico last year Novo Nordisk is also struggling to promote the new oral diabetes drug og217sc, which is an oral preparation of semaglutide, a glucagon like peptide-1 (- GLP-1) analogue injected once a week by Novo Nordisk Strong sales of new products in the R & D pipeline and existing diabetes drugs will help the company move closer to its goal of doubling sales in 10 years Last year, Carl Schultz, CEO of Novo Nordisk, said that by 2020, 40 million people with diabetes will use Novo Nordisk's products, making its annual growth not less than 10% Sanofi can only be ranked the second in the top 10 global data in terms of sales revenue of diabetes drugs Although the sales revenue of diabetes drugs in 2014 was also as high as $10.7 billion, its blockbuster drugs (insulin glargine, Lantus) were slightly lower than the sales revenue of the company's leading players In the first quarter of 2015, the sales revenue of Laishi (insulin glargine, Lantus) was 1.6 billion euros, but the global sales revenue decreased by 5% and the sales revenue of the United States decreased by 13%, mainly due to the price pressure and challenges brought by biological similar drugs However, the new diabetes drug GLP-1 receptor agonist lixisentide, lyxumia, toujeo, a smaller injection of Laishi (insulin glargine, Lantus), and afrezza, which inhaled insulin, are expected to boost their sales, thus slowing down the impact of biological analogues of Laishi (insulin glargine, Lantus) MSD has occupied the third place in the top ten global data diabetes drugs sales revenue In 2014, the sales revenue of diabetes drugs was $7.4 billion, down 0.7% year on year Mosadon had expected sitagliptin and januvia, inhibitors of DPP-4, to make a strong contribution to the company, but the company would face the dual challenges of sitagliptin generic drugs and sigagliptin and janumet MSD is still promoting DPP-4 products and recently announced that sitagliptin and januvia have passed a key heart safety test This positive result will be enough to support the sales revenue of sitagliptin, januvia, sitagliptin and janumet to increase by 10% by 2020, said Tim Anderson, an analyst at Bernstein, when he heard the news Pfizer and Lilly are the fourth and fifth largest in global data's top 10 global diabetes medicine sales revenue, respectively, with Pfizer's global diabetes medicine sales revenue of US $7.3 billion and Lilly's global diabetes medicine sales revenue of US $4.5 billion Pfizer is striving to continue to expand in the field of diabetes drugs, as the company signed an agreement to jointly promote new diabetes drugs in MSD in 2013 At the same time, Lilly is relying on its fast acting insulin, ubilog, to increase its sales before the new diabetes drug, glucagon like peptide 1 (GLP-1) receptor agonist dulaglutide, trulicity In addition, glixambi, glixambi and synjardy, which are jointly sold by Lilly and bringlingham, will contribute to Lilly in the future.